FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3099808521> ?p ?o ?g. }

• W3099808521 endingPage "966" @default.
• W3099808521 startingPage "957" @default.
• W3099808521 abstract "Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-ORhydroxychloroquine 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-ORantiviral 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399." @default.
• W3099808521 created "2020-11-23" @default.
• W3099808521 creator A5000077303 @default.
• W3099808521 creator A5000441617 @default.
• W3099808521 creator A5003760753 @default.
• W3099808521 creator A5005269604 @default.
• W3099808521 creator A5009084206 @default.
• W3099808521 creator A5009229154 @default.
• W3099808521 creator A5011981189 @default.
• W3099808521 creator A5012825403 @default.
• W3099808521 creator A5013853311 @default.
• W3099808521 creator A5016885016 @default.
• W3099808521 creator A5018145028 @default.
• W3099808521 creator A5019459208 @default.
• W3099808521 creator A5021035768 @default.
• W3099808521 creator A5022649152 @default.
• W3099808521 creator A5025836371 @default.
• W3099808521 creator A5027515412 @default.
• W3099808521 creator A5032391127 @default.
• W3099808521 creator A5033242180 @default.
• W3099808521 creator A5035250509 @default.
• W3099808521 creator A5036797392 @default.
• W3099808521 creator A5037881065 @default.
• W3099808521 creator A5038372910 @default.
• W3099808521 creator A5038577262 @default.
• W3099808521 creator A5041075483 @default.
• W3099808521 creator A5043709291 @default.
• W3099808521 creator A5043837522 @default.
• W3099808521 creator A5046580890 @default.
• W3099808521 creator A5047073906 @default.
• W3099808521 creator A5047834835 @default.
• W3099808521 creator A5048719508 @default.
• W3099808521 creator A5050477110 @default.
• W3099808521 creator A5050749081 @default.
• W3099808521 creator A5052006329 @default.
• W3099808521 creator A5053708022 @default.
• W3099808521 creator A5057523640 @default.
• W3099808521 creator A5058529428 @default.
• W3099808521 creator A5059014152 @default.
• W3099808521 creator A5060984872 @default.
• W3099808521 creator A5062419379 @default.
• W3099808521 creator A5070915829 @default.
• W3099808521 creator A5072715877 @default.
• W3099808521 creator A5075248311 @default.
• W3099808521 creator A5076746852 @default.
• W3099808521 creator A5076935142 @default.
• W3099808521 creator A5078199533 @default.
• W3099808521 creator A5081511751 @default.
• W3099808521 creator A5082217562 @default.
• W3099808521 creator A5084292168 @default.
• W3099808521 creator A5085803760 @default.
• W3099808521 date "2020-11-09" @default.
• W3099808521 modified "2023-10-18" @default.
• W3099808521 title "Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry" @default.
• W3099808521 cites W1984064716 @default.
• W3099808521 cites W1985181188 @default.
• W3099808521 cites W2029971767 @default.
• W3099808521 cites W2039679003 @default.
• W3099808521 cites W2106671991 @default.
• W3099808521 cites W2137673012 @default.
• W3099808521 cites W2341244791 @default.
• W3099808521 cites W3001118548 @default.
• W3099808521 cites W3005212621 @default.
• W3099808521 cites W3008028633 @default.
• W3099808521 cites W3008443627 @default.
• W3099808521 cites W3008827533 @default.
• W3099808521 cites W3009389929 @default.
• W3099808521 cites W3009489304 @default.
• W3099808521 cites W3009885589 @default.
• W3099808521 cites W3011152298 @default.
• W3099808521 cites W3011439019 @default.
• W3099808521 cites W3011605790 @default.
• W3099808521 cites W3012379316 @default.
• W3099808521 cites W3012421327 @default.
• W3099808521 cites W3012747666 @default.
• W3099808521 cites W3012925204 @default.
• W3099808521 cites W3013025026 @default.
• W3099808521 cites W3013376849 @default.
• W3099808521 cites W3023787531 @default.
• W3099808521 doi "https://doi.org/10.1007/s11739-020-02543-5" @default.
• W3099808521 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7649104" @default.
• W3099808521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33165755" @default.
• W3099808521 hasPublicationYear "2020" @default.
• W3099808521 type Work @default.
• W3099808521 sameAs 3099808521 @default.
• W3099808521 citedByCount "21" @default.
• W3099808521 countsByYear W30998085212020 @default.
• W3099808521 countsByYear W30998085212021 @default.
• W3099808521 countsByYear W30998085212022 @default.
• W3099808521 countsByYear W30998085212023 @default.
• W3099808521 crossrefType "journal-article" @default.
• W3099808521 hasAuthorship W3099808521A5000077303 @default.
• W3099808521 hasAuthorship W3099808521A5000441617 @default.
• W3099808521 hasAuthorship W3099808521A5003760753 @default.
• W3099808521 hasAuthorship W3099808521A5005269604 @default.
• W3099808521 hasAuthorship W3099808521A5009084206 @default.
• W3099808521 hasAuthorship W3099808521A5009229154 @default.
• W3099808521 hasAuthorship W3099808521A5011981189 @default.

• next